A summary of the included study characteristics. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

PDRN decreases the expression of cellular aging markers. by Jingjing Chen (293564)

<i>SLC2A2</i> is essential for liver differentiation in developing vertebrates by Yejin Kim (740789)

Subjects:

Effects of GJE extract treatment decreased serum ALT and AST levels. by Natnicha Suttawong (22367172)

Effects of GJE extract treatment decreased accumulation of Col1a1. by Natnicha Suttawong (22367172)

Effects of GJE extract treatment decreased expression of NF-kB p65. by Natnicha Suttawong (22367172)

“…Data are expressed as mean ± SD, error bars indicate standard deviation, n = 6/group. a: when compared to the control group. b: when compared to the NF group, <i><i>p</i></i> < 0.05 for both a and b.…”

MYCN overexpression leads to decreased <i>id2a</i> expression in early SCG. by Rodrigo Ibarra-García-Padilla (19697623)

A flow diagram of the study entry. by Sakiko Fukui (387048)

“…Criteria included: at least six months’ residency before death, ability to eat orally during the study period, and death within the facility. We created a time-series dataset for 69 participants, documenting their average weekly food intake (on a scale of 0-10). …”

Deep crypt secretory (DCS) cells are predominantly distributed in the proximal colon, with a progressive decrease towards the distal colon. by Daisuke Sugahara (2047696)

List of Included studies. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

The search strategy in three databases. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

NIH score. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

List of excluded studies. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

Image 7_Exploration of the diagnostic and prognostic roles of decreased autoantibodies in lung cancer.tif by Ying Ye (72583)

“…Diagnosing malignant small lung nodules (≤3cm) in CT scans remains a challenge in clinical practice.</p>Methods<p>In this study, we applied the HuProt array and the bioinformatics analysis to assess the diagnostic values of the decreased autoantibodies in lung cancers.…”

Image 6_Exploration of the diagnostic and prognostic roles of decreased autoantibodies in lung cancer.tif by Ying Ye (72583)

“…Diagnosing malignant small lung nodules (≤3cm) in CT scans remains a challenge in clinical practice.</p>Methods<p>In this study, we applied the HuProt array and the bioinformatics analysis to assess the diagnostic values of the decreased autoantibodies in lung cancers.…”

Image 3_Exploration of the diagnostic and prognostic roles of decreased autoantibodies in lung cancer.tif by Ying Ye (72583)

“…Diagnosing malignant small lung nodules (≤3cm) in CT scans remains a challenge in clinical practice.</p>Methods<p>In this study, we applied the HuProt array and the bioinformatics analysis to assess the diagnostic values of the decreased autoantibodies in lung cancers.…”

Image 1_Exploration of the diagnostic and prognostic roles of decreased autoantibodies in lung cancer.tif by Ying Ye (72583)

“…Diagnosing malignant small lung nodules (≤3cm) in CT scans remains a challenge in clinical practice.</p>Methods<p>In this study, we applied the HuProt array and the bioinformatics analysis to assess the diagnostic values of the decreased autoantibodies in lung cancers.…”

Image 2_Exploration of the diagnostic and prognostic roles of decreased autoantibodies in lung cancer.tif by Ying Ye (72583)

“…Diagnosing malignant small lung nodules (≤3cm) in CT scans remains a challenge in clinical practice.</p>Methods<p>In this study, we applied the HuProt array and the bioinformatics analysis to assess the diagnostic values of the decreased autoantibodies in lung cancers.…”

Image 4_Exploration of the diagnostic and prognostic roles of decreased autoantibodies in lung cancer.tif by Ying Ye (72583)

“…Diagnosing malignant small lung nodules (≤3cm) in CT scans remains a challenge in clinical practice.</p>Methods<p>In this study, we applied the HuProt array and the bioinformatics analysis to assess the diagnostic values of the decreased autoantibodies in lung cancers.…”

Image 5_Exploration of the diagnostic and prognostic roles of decreased autoantibodies in lung cancer.tif by Ying Ye (72583)

“…Diagnosing malignant small lung nodules (≤3cm) in CT scans remains a challenge in clinical practice.</p>Methods<p>In this study, we applied the HuProt array and the bioinformatics analysis to assess the diagnostic values of the decreased autoantibodies in lung cancers.…”